Treatment of spasticity with botulinum toxin.
Identifieur interne : 000F93 ( PubMed/Corpus ); précédent : 000F92; suivant : 000F94Treatment of spasticity with botulinum toxin.
Auteurs : Yasuhiko Baba M D ; Michael D. Osborne M D ; Zbigniew K. Wszolek M D ; Andrzej Kwolek ; Mariusz Druzbicki Ph DSource :
- Ortopedia, traumatologia, rehabilitacja [ 1509-3492 ] ; 2004.
Abstract
Spasticity is a complex disorder characterized by a velocity-dependent increase in muscle tone associated with exaggerated deep tendon reflexes. It can be caused by numerous diffuse or focal cerebral and spinal pathologic conditions. Spasticity indicates upper motor neuron dysfunction and if severe, can lead to considerable motion restriction and eventually to more serious disability. The therapeutic interventions available to treat spasticity are often of limited benefit. In the last decade, many open-label and several double-blind, placebo-controlled, studies have demonstrated the effectiveness of intramuscular botulinum toxin (BTX) injections for the management of spasticity caused by multiple sclerosis, brain / spinal cord injury, cerebral palsy, and stroke. BTX can also be beneficial in the treatment of spasticity, or a mixture of spasticity and rigidity, in many neurodegenerative conditions; including Parkinson disease, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia and parkinsonism linked to chromosome 17, and in various sporadic and familial spinocerebellar ataxia syndromes. Currently, two BTX serotypes, which are serologically different but share a common subunit structure, are commercially available: type A (Botox(R), manufactured by Allergan, Inc, Irvine, California, USA; and Dysport(R), distributed by Beaufour-Ipsen Pharmaceuticals, Paris, France); and type B (manufactured by Elan Corporation, Dublin, Ireland, and available in the United States as MyoBloc(R) and in Europe as NeuroBloc(R)). BTX primarily affects the neuromuscular junction by inhibiting acetylcholine release. Dosages vary considerably depending on the particular preparation used, the muscle injected, the severity of the condition, and the duration of treatment.
PubMed: 17618218
Links to Exploration step
pubmed:17618218Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of spasticity with botulinum toxin.</title><author><name sortKey="Baba M D, Yasuhiko" sort="Baba M D, Yasuhiko" uniqKey="Baba M D Y" first="Yasuhiko" last="Baba M D">Yasuhiko Baba M D</name><affiliation><nlm:affiliation>Department of Neurology, Mayo Clinic Jacksonville, FL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Osborne M D, Michael D" sort="Osborne M D, Michael D" uniqKey="Osborne M D M" first="Michael D" last="Osborne M D">Michael D. Osborne M D</name></author><author><name sortKey="Wszolek M D, Zbigniew K" sort="Wszolek M D, Zbigniew K" uniqKey="Wszolek M D Z" first="Zbigniew K" last="Wszolek M D">Zbigniew K. Wszolek M D</name></author><author><name sortKey="Kwolek, Andrzej" sort="Kwolek, Andrzej" uniqKey="Kwolek A" first="Andrzej" last="Kwolek">Andrzej Kwolek</name></author><author><name sortKey="Druzbicki Ph D, Mariusz" sort="Druzbicki Ph D, Mariusz" uniqKey="Druzbicki Ph D M" first="Mariusz" last="Druzbicki Ph D">Mariusz Druzbicki Ph D</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:17618218</idno><idno type="pmid">17618218</idno><idno type="wicri:Area/PubMed/Corpus">000F93</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of spasticity with botulinum toxin.</title><author><name sortKey="Baba M D, Yasuhiko" sort="Baba M D, Yasuhiko" uniqKey="Baba M D Y" first="Yasuhiko" last="Baba M D">Yasuhiko Baba M D</name><affiliation><nlm:affiliation>Department of Neurology, Mayo Clinic Jacksonville, FL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Osborne M D, Michael D" sort="Osborne M D, Michael D" uniqKey="Osborne M D M" first="Michael D" last="Osborne M D">Michael D. Osborne M D</name></author><author><name sortKey="Wszolek M D, Zbigniew K" sort="Wszolek M D, Zbigniew K" uniqKey="Wszolek M D Z" first="Zbigniew K" last="Wszolek M D">Zbigniew K. Wszolek M D</name></author><author><name sortKey="Kwolek, Andrzej" sort="Kwolek, Andrzej" uniqKey="Kwolek A" first="Andrzej" last="Kwolek">Andrzej Kwolek</name></author><author><name sortKey="Druzbicki Ph D, Mariusz" sort="Druzbicki Ph D, Mariusz" uniqKey="Druzbicki Ph D M" first="Mariusz" last="Druzbicki Ph D">Mariusz Druzbicki Ph D</name></author></analytic><series><title level="j">Ortopedia, traumatologia, rehabilitacja</title><idno type="ISSN">1509-3492</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Spasticity is a complex disorder characterized by a velocity-dependent increase in muscle tone associated with exaggerated deep tendon reflexes. It can be caused by numerous diffuse or focal cerebral and spinal pathologic conditions. Spasticity indicates upper motor neuron dysfunction and if severe, can lead to considerable motion restriction and eventually to more serious disability. The therapeutic interventions available to treat spasticity are often of limited benefit. In the last decade, many open-label and several double-blind, placebo-controlled, studies have demonstrated the effectiveness of intramuscular botulinum toxin (BTX) injections for the management of spasticity caused by multiple sclerosis, brain / spinal cord injury, cerebral palsy, and stroke. BTX can also be beneficial in the treatment of spasticity, or a mixture of spasticity and rigidity, in many neurodegenerative conditions; including Parkinson disease, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia and parkinsonism linked to chromosome 17, and in various sporadic and familial spinocerebellar ataxia syndromes. Currently, two BTX serotypes, which are serologically different but share a common subunit structure, are commercially available: type A (Botox(R), manufactured by Allergan, Inc, Irvine, California, USA; and Dysport(R), distributed by Beaufour-Ipsen Pharmaceuticals, Paris, France); and type B (manufactured by Elan Corporation, Dublin, Ireland, and available in the United States as MyoBloc(R) and in Europe as NeuroBloc(R)). BTX primarily affects the neuromuscular junction by inhibiting acetylcholine release. Dosages vary considerably depending on the particular preparation used, the muscle injected, the severity of the condition, and the duration of treatment.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">17618218</PMID><DateCreated><Year>2007</Year><Month>07</Month><Day>09</Day></DateCreated><DateCompleted><Year>2012</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2007</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1509-3492</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Month>Oct</Month><Day>30</Day></PubDate></JournalIssue><Title>Ortopedia, traumatologia, rehabilitacja</Title><ISOAbbreviation>Ortop Traumatol Rehabil</ISOAbbreviation></Journal><ArticleTitle>Treatment of spasticity with botulinum toxin.</ArticleTitle><Pagination><MedlinePgn>665-72</MedlinePgn></Pagination><Abstract><AbstractText>Spasticity is a complex disorder characterized by a velocity-dependent increase in muscle tone associated with exaggerated deep tendon reflexes. It can be caused by numerous diffuse or focal cerebral and spinal pathologic conditions. Spasticity indicates upper motor neuron dysfunction and if severe, can lead to considerable motion restriction and eventually to more serious disability. The therapeutic interventions available to treat spasticity are often of limited benefit. In the last decade, many open-label and several double-blind, placebo-controlled, studies have demonstrated the effectiveness of intramuscular botulinum toxin (BTX) injections for the management of spasticity caused by multiple sclerosis, brain / spinal cord injury, cerebral palsy, and stroke. BTX can also be beneficial in the treatment of spasticity, or a mixture of spasticity and rigidity, in many neurodegenerative conditions; including Parkinson disease, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia and parkinsonism linked to chromosome 17, and in various sporadic and familial spinocerebellar ataxia syndromes. Currently, two BTX serotypes, which are serologically different but share a common subunit structure, are commercially available: type A (Botox(R), manufactured by Allergan, Inc, Irvine, California, USA; and Dysport(R), distributed by Beaufour-Ipsen Pharmaceuticals, Paris, France); and type B (manufactured by Elan Corporation, Dublin, Ireland, and available in the United States as MyoBloc(R) and in Europe as NeuroBloc(R)). BTX primarily affects the neuromuscular junction by inhibiting acetylcholine release. Dosages vary considerably depending on the particular preparation used, the muscle injected, the severity of the condition, and the duration of treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baba M D</LastName><ForeName>Yasuhiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osborne M D</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Wszolek M D</LastName><ForeName>Zbigniew K</ForeName><Initials>ZK</Initials></Author><Author ValidYN="Y"><LastName>Kwolek</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Druzbicki Ph D</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Ortop Traumatol Rehabil</MedlineTA><NlmUniqueID>101240146</NlmUniqueID><ISSNLinking>1509-3492</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>10</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17618218</ArticleId><ArticleId IdType="pii">15750</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000F93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17618218
|texte= Treatment of spasticity with botulinum toxin.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17618218" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |